Afelimomab
| Monoclonal antibody | |
|---|---|
| Type | F(ab')2 fragment |
| Source | Mouse |
| Target | TNFα |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
  (what is this?) (verify) | |
Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]
References
- ^ Rondon, E.; Venkataraman, R. (2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care. 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Panacek, E. A.; Marshall, J. C.; Albertson, T. E.; Johnson, D. H.; Johnson, S.; MacArthur, R. D.; Miller, M.; Barchuk, W. T.; Fischkoff, S.; Kaul, M.; Teoh, L.; Van Meter, L.; Daum, L.; Lemeshow, S.; Hicklin, G.; Doig, C.; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators (2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine. 32 (11): 2173–2182. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |